Prochlorperazine maleate - Generic Drug Details

What are the generic drug sources for prochlorperazine maleate and what is the scope of patent protection?

Prochlorperazine maleate is the generic ingredient in four branded drugs marketed by Glaxosmithkline, Watson Labs, Ajanta Pharma Ltd, Amneal, Aurobindo Pharma Ltd, Bionpharma, Chartwell Rx, Dr Reddys Labs Sa, Duramed Pharms Barr, Glenmark Pharms Ltd, Ivax Sub Teva Pharms, Leading, Novitium Pharma, Pharmobedient, Teva Pharms, Zydus Lifesciences, and Jubilant Cadista, and is included in twenty-four NDAs. Additional information is available in the individual branded drug profile pages.

There are eight drug master file entries for prochlorperazine maleate. Twenty-eight suppliers are listed for this compound.

Summary for prochlorperazine maleate

US Patents:	0
Tradenames:	4
Applicants:	17
NDAs:	24
Drug Master File Entries:	8
Finished Product Suppliers / Packagers:	28
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	2,305
Drug Prices:	Drug price trends for prochlorperazine maleate
What excipients (inactive ingredients) are in prochlorperazine maleate?	prochlorperazine maleate excipients list
DailyMed Link:	prochlorperazine maleate at DailyMed

See drug prices for prochlorperazine maleate

See drug sales revenues for prochlorperazine maleate

Recent Clinical Trials for prochlorperazine maleate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Colorado, Denver	PHASE2

See all prochlorperazine maleate clinical trials

Pharmacology for prochlorperazine maleate

Drug Class

Phenothiazine

Anatomical Therapeutic Chemical (ATC) Classes for prochlorperazine maleate

N05AB	Phenothiazines with piperazine structure
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

N05AB	Phenothiazines with piperazine structure
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for prochlorperazine maleate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jubilant Cadista	PROCOMP	prochlorperazine maleate	TABLET;ORAL	040268-001	Feb 27, 1998	AB	RX	No	No
Chartwell Rx	PROCHLORPERAZINE MALEATE	prochlorperazine maleate	TABLET;ORAL	040101-001	Jul 19, 1996		DISCN	No	No
Aurobindo Pharma Ltd	PROCHLORPERAZINE MALEATE	prochlorperazine maleate	TABLET;ORAL	218734-001	Sep 8, 2025	AB	RX	No	No

Market Dynamics and Financial Trajectory for Prochlorperazine Maleate

Last updated: February 20, 2026

What Is the Current Market Size and Demand for Prochlorperazine Maleate?

Prochlorperazine maleate primarily treats nausea, vomiting, and vertigo. It is available in oral, rectal, and injectable forms. The global antiemetic drugs market was valued at approximately USD 4.7 billion in 2022 and is projected to reach USD 7.2 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.4%[1].

As a generic in most markets, prochlorperazine maleate accounts for a significant share of demand driven by hospitals and clinics. The molecule’s low-to-moderate cost and widespread off-label use bolster steady demand.

Key demand factors include:

• Increasing prevalence of nausea related to chemotherapy, surgery, and other medical procedures.
• Aging populations experiencing higher vertigo and dementia-related symptoms.
• Limited innovation in alternative antiemetic therapies, favoring existing treatments like prochlorperazine.

How Does Competition Affect Market Share and Pricing?

Prochlorperazine maleate faces competition primarily from newer antiemetic agents such as ondansetron, promethazine, and metoclopramide. These newer drugs often offer reduced side effects and targeted mechanisms of action, impacting market share.

Pricing varies by region:

Region	Average Price (per 10 mg tablet or equivalent)	Market Share of Prochlorperazine Maleate (%)
North America	USD 0.10 – 0.15	35 – 45
Europe	USD 0.08 – 0.13	30 – 40
Asia-Pacific	USD 0.05 – 0.12	20 – 35
Latin America	USD 0.07 – 0.10	15 – 25

Generics hold over 80% of prescriptions in mature markets, exerting downward pressure on prices. Brand-name formulations are priced higher but represent a minor share of the total volume.

What Are the Regulatory and Patent Trends Influencing the Market?

Prochlorperazine's patent protections largely expired in the late 20th century, making it a widely accessible generic. This widespread availability limits pricing power for original developers but ensures continuous supply.

Regulatory scrutiny has increased over safety concerns:

• Risks of extrapyramidal symptoms and neuroleptic malignant syndrome.
• Use restrictions in certain populations, such as pediatric patients, with warnings issued by agencies like the FDA and EMA[2].

No major patent litigations or exclusivity periods remain; thus, market entry barriers are minimal.

How Will Technological and Clinical Developments Impact Financial Outlook?

Advances in antiemetic therapy, such as NK1 receptor antagonists and 5-HT3 receptor antagonists, exert competitive pressure. However, the consolidated cost benefits of generics maintain prochlorperazine maleate's relevance.

Potential innovations could include:

• Formulation improvements to reduce side effects.
• Combination therapies with newer agents.

These innovations influence future pricing and adoption but are unlikely to displace the molecule’s core position entirely in the short term.

What Are the Revenue Projections and Investment Opportunities?

The consistent demand combined with low-cost manufacturing suggests stable revenues for manufacturers of generic prochlorperazine maleate.

Projected revenue growth is aligned with the overall antiemetics market CAGR of 5.4%. In 2022, market estimates for prochlorperazine products are around USD 600 million globally[3].

Opportunities lie in:

• Expanding production in emerging markets where healthcare infrastructure improves.
• Developing combination formulations to address specific conditions.
• Diversifying into niche indications such as migraine-related nausea.

Investors can anticipate continued revenue stability, with modest growth driven by increased healthcare access and off-label usage.

Conclusion

Prochlorperazine maleate remains a staple in antiemetic therapy predominantly through generics. Its market is characterized by steady demand, price competition, and limited innovation pressure. The financial trajectory depends primarily on regional healthcare policies, regulatory standards, and competition from newer agents.

Key Takeaways

• The global antiemetic market is projected to grow at over 5% annually, with prochlorperazine maleate maintaining a significant share.
• Generic competition drives lower prices, but stable demand sustains revenue streams.
• Regulatory concerns focus on safety, with no significant patent protections limiting market entry.
• Future growth relies on market expansion in emerging regions and potential formulation innovations.

FAQs

1. How is prochlorperazine maleate positioned against newer antiemetics?
   It competes primarily on cost and established efficacy. Newer agents may offer fewer side effects but are more expensive and less widely available as generics.

2. Are there any upcoming patent protections or exclusivities?
   No; patent protections for prochlorperazine maleate have expired.

3. What are the main regulatory concerns?
   Risks of extrapyramidal symptoms and neuroleptic malignant syndrome have led to warnings and restricted use in certain populations.

4. How does regional variation affect the market?
   Developing regions show higher growth potential due to improving healthcare infrastructure, despite lower per-unit prices.

5. What investment risks exist for companies manufacturing prochlorperazine?
   Market saturation, price undercutting from generics, and the rise of newer therapies pose primary risks.

---

References

[1] MarketWatch. (2023). Anti-Emetics Market Size, Share & Trends Analysis.
[2] U.S. Food and Drug Administration. (2022). Safety Warnings for Prochlorperazine.
[3] Grand View Research. (2022). Global Anti-Emetics Market Forecast.